Impact of Vyvgart (Efgartigimod Alfa) Approval for Patients with Seronegative Myasthenia Gravis by Madaline Spencer| Published on: Jun 15, 2026

Impact of Vyvgart (Efgartigimod Alfa) Approval for Patients with Seronegative Myasthenia Gravis by Madaline Spencer| Published on: Jun 15, 2026 Jeff Guptill, MD, Neuromuscular Clinical Development Lead at Argenx, discusses the impact of the Vyvgart (efgartigimod alfa) approval on the myasthenia gravis (MG) community to treat patients with anti-MuSK-Ab positive, anti-LRP4-Ab positive, and/or triple seronegative MG. https://checkrare.com/impact-of-vyvgart-efgartigimod-alfa-approval-for-patients-with-seronegative-myasthenia-gravis/